Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors. The company focuses on advancing its proprietary ex vivo genetic and epigenetic reprogramming technologies, Gen-R and Epi-R, to address major barriers to successful adoptive T-cell therapy, primarily T-cell exhaustion and lack of durable stemness. Their pipeline includes product candidates targeting various solid tumor indications.
The headquarters serves as the central corporate office, housing executive leadership, core research and development laboratories, and essential administrative and operational functions.
Features state-of-the-art research and development laboratories specifically designed for cutting-edge cell therapy innovation. The facility likely incorporates modern, collaborative workspaces conducive to scientific discovery, typical of leading biotech companies.
Characterized by a fast-paced, science-driven, and highly collaborative environment. There is a strong emphasis on innovation, scientific rigor, and a patient-centric approach to developing transformative cancer therapies.
Its location in South San Francisco provides critical access to a rich ecosystem of talent, renowned research institutions, potential collaborators, and venture capital, vital for a clinical-stage biotech company.
Lyell Immunopharma's primary operations, including research, corporate functions, and manufacturing, are based in the United States (California and Washington). While their therapies are being developed for global patient populations, their physical presence is currently concentrated in the U.S. Clinical trials for their product candidates may involve sites internationally, extending their operational reach in collaboration with research partners and clinical investigators worldwide.
201 Haskins Way
South San Francisco
CA
USA
Address: 11804 North Creek Parkway S, Bothell, WA 98011
Leverages the Seattle/Bothell region's established biotechnology sector and skilled workforce specializing in biomanufacturing and process development, supporting Lyell's clinical and future commercial supply needs.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Lyell Immunopharma' leadership includes:
Lyell Immunopharma has been backed by several prominent investors over the years, including:
Over the past 12 months (approx. mid-2023 to mid-2024), Lyell Immunopharma appointed Charlie Newton as Chief Financial Officer and promoted Thérèse (“Tina”) M. Albertson to Chief People and Technical Operations Officer. No C-suite executive departures were publicly announced during this period.
Discover the tools Lyell Immunopharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Lyell Immunopharma likely utilizes standard corporate email address formats. Common patterns include the first initial followed by the last name, or first name separated from the last name by a period.
flast@lyell.com (e.g., jdoe@lyell.com) or first.last@lyell.com (e.g., jane.doe@lyell.com)
Format
lhomans@lyell.com
Example
85%
Success rate
GlobeNewswire • May 7, 2024
Lyell Immunopharma announced its financial results for the first quarter ended March 31, 2024, and provided updates on its clinical programs, LYL797 and LYL845, highlighting ongoing patient dosing and site activation for its Phase 1 trials in solid tumors....more
GlobeNewswire • February 27, 2024
The company reported its financial results for the fourth quarter and full year 2023, discussed advancements in its pipeline of T-cell therapies incorporating Gen-R and Epi-R technologies, and outlined key strategic priorities and anticipated milestones for 2024....more
GlobeNewswire • November 3, 2023
Lyell presented initial safety, cell product characterization, and correlative science data from its Phase 1 trial of LYL797, an ROR1-targeted CAR T-cell therapy enhanced with Gen-R and Epi-R, in patients with ROR1+ non-small cell lung cancer and triple-negative breast cancer....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Lyell Immunopharma, are just a search away.